Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 Bioavailability and PK Study
NCT05330858Phase 1Completed
- Sponsor
- Alumis Inc.
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of envudeucitinib in plaque psoriasis and systemic lupus erythematosus (SLE) (4 arms), sponsored by Alumis Inc. Primary endpoints: Time of Maximum Plasma Concentration at 18 days, Maximum Plasma Concentration at 18 days and 1 more. Started Mar 2022; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasissystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05330858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330858.